Effect of the malaria vaccine Combination B on merozoite surface antigen 2 diversity
Authors:
- Christian FlückCFChristian Flück
- Sonja SchöpflinSSSonja Schöpflin
- Tom SmithTSTom Smith
- Blaise GentonBGBlaise Genton
- Michael P. AlpersMAMichael P. Alpers
- Hans-Peter BeckHBHans-Peter Beck
- Ingrid FelgerIFIngrid Felger
- 1 January 2007
- journal article
- clinical trial
- Published by Elsevier in Infection, Genetics and Evolution
- Vol. 7 (1) , 44-51
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Strain-Specific Humoral Response to a Polymorphic Malaria VaccineInfection and Immunity, 2004
- Progress in the development of recombinant and synthetic blood-stage malaria vaccinesJournal of Experimental Biology, 2003
- Molecular monitoring in malaria vaccine trialsTrends in Parasitology, 2003
- A Recombinant Blood‐Stage Malaria Vaccine ReducesPlasmodium falciparumDensity and Exerts Selective Pressure on Parasite Populations in a Phase 1–2b Trial in Papua New GuineaThe Journal of Infectious Diseases, 2002
- Imperfect vaccines and the evolution of pathogen virulenceNature, 2001
- Two novel alleles within subfamilies of the merozoite surface antigen 2 (MSA-2) of Plasmodium falciparumMolecular and Biochemical Parasitology, 1992
- Immunological fine structure of the variable and constant regions of a polymorphic malarial surface antigen from Plasmodium falciparumMolecular and Biochemical Parasitology, 1991
- On the function of repetitive domains in protein antigens of Plasmodium and other eukaryotic parasitesParasitology Today, 1991
- Repetitive Proteins and Genes of MalariaAnnual Review of Microbiology, 1987
- Multiple cross‐reactivities amongst antigens of Plasmodium falciparum impair the development of protective immunity against malariaParasite Immunology, 1986